Cargando…
Targeting the mevalonate pathway is a novel therapeutic approach to inhibit oncogenic FoxM1 transcription factor in human hepatocellular carcinoma
Dysregulation of cell metabolism is a hallmark of cancer. The mevalonate pathway in lipid metabolism has been implicated as a potential target of cancer therapy for hepatocellular carcinoma (HCC). The role of the Forkhead Box M1 (FoxM1) transcription factor in HCC development has been well documente...
Autores principales: | Ogura, Satoshi, Yoshida, Yuichi, Kurahashi, Tomohide, Egawa, Mayumi, Furuta, Kunimaro, Kiso, Shinichi, Kamada, Yoshihiro, Hikita, Hayato, Eguchi, Hidetoshi, Ogita, Hisakazu, Doki, Yuichiro, Mori, Masaki, Tatsumi, Tomohide, Takehara, Tetsuo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940385/ https://www.ncbi.nlm.nih.gov/pubmed/29765517 http://dx.doi.org/10.18632/oncotarget.24781 |
Ejemplares similares
-
Forkhead Box M1 Transcription Factor Drives Liver Inflammation Linking to Hepatocarcinogenesis in Mice
por: Kurahashi, Tomohide, et al.
Publicado: (2019) -
Increased Bcl-xL Expression in Pancreatic Neoplasia Promotes Carcinogenesis by Inhibiting Senescence and Apoptosis
por: Ikezawa, Kenji, et al.
Publicado: (2017) -
Lipid overloading during liver regeneration causes delayed hepatocyte DNA replication by increasing ER stress in mice with simple hepatic steatosis
por: Hamano, Mina, et al.
Publicado: (2013) -
CEACAM1 Is Associated With the Suppression of Natural Killer Cell Function in Patients With Chronic Hepatitis C
por: Suda, Takahiro, et al.
Publicado: (2018) -
CRISPR Loss-of-Function Screen Identifies the Hippo Signaling Pathway as the Mediator of Regorafenib Efficacy in Hepatocellular Carcinoma
por: Suemura, Shigeki, et al.
Publicado: (2019)